- Page 1 and 2: DRIVIN G ROWTH Dr. Reddy’s Labora
- Page 3 and 4: sales of branded formulations grew
- Page 5 and 6: THE ULTIMATE ACCOLADE FOR A PHARMAC
- Page 7 and 8: IT TAKES COURAGE AND VISION TO LOOK
- Page 9 and 10: 1997 Entered: Phase I clinical tria
- Page 11 and 12: 1987 USFDA Inspection: Ibuprofen fa
- Page 13 and 14: 1999 Submitted: ANDA for Omeprazole
- Page 15 and 16: 1995 Established: Reddy- Biomed; ou
- Page 17 and 18: ARMED WITH A HIGHLY MOTIVATED AND C
- Page 19 and 20: K ILO L AB FACILITY at Technology D
- Page 21 and 22: SHE PRACTICES HAVE EVOLVED FROM AN
- Page 23 and 24: ADOPTING A COMPETENCY-BASED FRAMEWO
- Page 25 and 26: THE HIGHEST PATRIOTISM AND PHILANTH
- Page 27 and 28: AFTER AN HOUR AT ROSHNI I LEFT WITH
- Page 29 and 30: and valuation THE DICTUM in any kno
- Page 31 and 32: total shareholder’s return “TOT
- Page 33 and 34: 4,585,070 equity shares of erstwhil
- Page 35 and 36: REDDY PHARMACEUTICALS HONG KONG LTD
- Page 37 and 38: Pathway enables Reddy US Therapeuti
- Page 39 and 40: AUDITORS THE AUDIT in the financial
- Page 41: 2.Benefits derived as a result of t
- Page 45 and 46: articulation of its corporate visio
- Page 47 and 48: THE LAUNCH OF FLUOXETINE HAS BEEN T
- Page 49 and 50: MUCH OF THE CASH FLOW ARISING OUT O
- Page 51 and 52: WITH THE ANTICIPATED GROWTH IN THE
- Page 53 and 54: CHART B NCE Pipeline Diabetes DRF N
- Page 55 and 56: AURIGENE WILL BUILD SKILLS IN AUTOM
- Page 57 and 58: The highlights of the scheme were:
- Page 59 and 60: INVESTMENTS INVESTMENTS reduced to
- Page 61 and 62: Rs. 108 million (US$ 2.25 million)
- Page 63 and 64: THE STRENGTH OF INDIA’S SCIENTIFI
- Page 65 and 66: internal accounting, administrative
- Page 67 and 68: e disproportionately distributed in
- Page 69 and 70: COMPOSITION AND MEETINGS OF THE BOA
- Page 71 and 72: Table 2 | Remuneration of the direc
- Page 73 and 74: (iii) Ms. G Anuradha (daughter of D
- Page 75 and 76: increase speed of reporting and cre
- Page 77 and 78: the Committee. The Investment Commi
- Page 79 and 80: MANAGEMENT DISCUSSION AND ANALYSIS
- Page 81 and 82: non-executive, independent Addition
- Page 83 and 84: press releases and conducts program
- Page 85 and 86: We state that no investor grievance
- Page 87 and 88: Media Bhaswati Banerjee / R. Rammoh
- Page 89 and 90: CODES AT VARIOUS STOCK EXCHANGES Th
- Page 91 and 92: EQUITY HISTORY OF THE COMPANY Table
- Page 93 and 94:
SHAREHOLDING PATTERN AS ON MARCH 31
- Page 95 and 96:
dematerialised form may contact the
- Page 97 and 98:
UNCLAIMED DIVIDENDS Pursuant to sec
- Page 99 and 100:
generics Survey No. 41 Bachupally Q
- Page 101 and 102:
financials 103
- Page 103 and 104:
annexure to the auditors’ report
- Page 105 and 106:
alance sheet | AS AT MARCH 31 (All
- Page 107 and 108:
schedules to the balance sheet | (A
- Page 109 and 110:
schedules to the balance sheet | (A
- Page 111 and 112:
schedules to the balance sheet | (A
- Page 113 and 114:
schedules to the balance sheet | (A
- Page 115 and 116:
schedules to the balance sheet | (A
- Page 117 and 118:
schedules to the profit and loss ac
- Page 119 and 120:
schedule to the balance sheet and p
- Page 121 and 122:
schedule to the balance sheet and p
- Page 123 and 124:
schedule to the balance sheet and p
- Page 125 and 126:
schedule to the balance sheet and p
- Page 127 and 128:
schedule to the balance sheet and p
- Page 129 and 130:
schedule to the balance sheet and p
- Page 131 and 132:
cash flow statement | YEAR ENDED MA
- Page 133 and 134:
auditors’ certificate To The Boar
- Page 135 and 136:
consolidated financials
- Page 137 and 138:
consolidated balance sheet | (All a
- Page 139 and 140:
schedules to the consolidated balan
- Page 141 and 142:
schedules to the consolidated balan
- Page 143 and 144:
schedules to the consolidated balan
- Page 145 and 146:
schedules to the consolidated profi
- Page 147 and 148:
schedule to the consolidated balanc
- Page 149 and 150:
schedule to the consolidated balanc
- Page 151 and 152:
schedule to the consolidated balanc
- Page 153 and 154:
schedule to the consolidated balanc
- Page 155 and 156:
schedule to the consolidated balanc
- Page 157 and 158:
schedule to the consolidated balanc
- Page 159 and 160:
schedule to the consolidated balanc
- Page 161 and 162:
cash flow statement | (contd...) YE
- Page 163 and 164:
statement under section 212
- Page 165 and 166:
The net Aggregate of profits (losse
- Page 167 and 168:
drl investments ltd.
- Page 169 and 170:
auditors’ report A RAMACHANDRA RA
- Page 171 and 172:
alance sheet | AS Schedule 2002 200
- Page 173 and 174:
schedules | AS AT MARCH 31 (Rs) 200
- Page 175 and 176:
schedules Schedule - 3.00 NOTES TO
- Page 177 and 178:
compact electric ltd.
- Page 179 and 180:
auditors’ report A RAMACHANDRA RA
- Page 181 and 182:
alance sheet | AS Schedule 2002 200
- Page 183 and 184:
schedules | AS AT MARCH 31 (Rs) 200
- Page 185 and 186:
schedules | AS AT MARCH 31 (Rs) 200
- Page 187 and 188:
schedules | FOR THE YEAR ENDED MARC
- Page 189 and 190:
schedules 7. The information requir
- Page 191 and 192:
alance sheet abstract and company
- Page 193 and 194:
eddy pharmaceuticals hong kong ltd.
- Page 195 and 196:
eport of the auditors ERNST & YOUNG
- Page 197 and 198:
profit and loss account | YEAR ENDE
- Page 199 and 200:
notes to financial statements - DEC
- Page 201 and 202:
notes to financial statements - DEC
- Page 203 and 204:
eddy biomed ltd.
- Page 205 and 206:
eport of sinay joint-stock company
- Page 207 and 208:
alance sheet | AS AT DECEMBER 31 (R
- Page 209 and 210:
eddy antilles n.v.
- Page 211 and 212:
alance sheet | AS AT DECEMBER 31 (U
- Page 213 and 214:
notes to the financial statements G
- Page 215 and 216:
dr. reddy’s farmacêutica do bras
- Page 217 and 218:
dr. reddy’s laboratories, inc.
- Page 219 and 220:
alance sheet | AS AT MARCH 31 (US $
- Page 221 and 222:
statement of cash flows | FOR THE Y
- Page 223 and 224:
notes to the financial statements n
- Page 225 and 226:
notes to the financial statements n
- Page 227 and 228:
eddy pharmaceuticals singapore pte
- Page 229 and 230:
9. DIVIDENDS No dividend has been p
- Page 231 and 232:
eport of the auditors to the member
- Page 233 and 234:
profit and loss statement | FOR sta
- Page 235 and 236:
notes to the financial statements -
- Page 237 and 238:
notes to the financial statements -
- Page 239 and 240:
eddy us therapeutics, inc
- Page 241 and 242:
alance sheet | AS AT MARCH 31 (US $
- Page 243 and 244:
statement of cash flows | FOR THE Y
- Page 245 and 246:
notes to financial statements 2.REL
- Page 247 and 248:
eddy cheminor s.a.
- Page 249 and 250:
alance sheet | Euros March 31, Fisc
- Page 251 and 252:
profit and loss account | FOR THE Y
- Page 253 and 254:
accounting rules and methods Annexe
- Page 255 and 256:
depreciation | AS Categories A Posi
- Page 257 and 258:
ageing analysis of debts receivable
- Page 259 and 260:
details of charges to be paid | AS
- Page 261 and 262:
effect of different fiscal provisio
- Page 263 and 264:
B - Agreements with Mr Luc Lamiraul
- Page 265 and 266:
cheminor investments ltd.
- Page 267 and 268:
auditors’ report A RAMACHANDRA RA
- Page 269 and 270:
alance sheet | AS AT MARCH 31 Parti
- Page 271 and 272:
schedules forming part of balance s
- Page 273 and 274:
alance sheet abstract and company
- Page 275 and 276:
aurigene discovery technologies ltd
- Page 277 and 278:
Acknowledgements The Directors take
- Page 279 and 280:
annexure to the auditors’ report
- Page 281 and 282:
profit and loss account | FOR EXPEN
- Page 283 and 284:
schedules forming part of the profi
- Page 285 and 286:
schedules forming part of the balan
- Page 287 and 288:
zenovus biotech pvt. ltd.
- Page 289 and 290:
auditors’ report A RAMACHANDRA RA
- Page 291 and 292:
schedules forming part of the balan
- Page 293 and 294:
schedules forming part of the balan
- Page 295 and 296:
kunshan rotam reddy pharmaceutical
- Page 297 and 298:
alance sheet | AS AT DECEMBER 31 (R
- Page 299 and 300:
income statement | FOR THE YEAR END
- Page 301 and 302:
notes to the financial statements 5
- Page 303 and 304:
eddy netherlands b.v.
- Page 305 and 306:
alance sheet | AS AT DECEMBER 31 (I
- Page 307 and 308:
general notes GENERAL COMMENTS The
- Page 309 and 310:
notice
- Page 311 and 312:
The remuneration payable by way of
- Page 313 and 314:
Item No. 9 The Company had appointe